Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen Inc.
Seagen Inc.
University of Michigan Rogel Cancer Center
City of Hope Medical Center
Elicio Therapeutics
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Elevation Oncology
National Cancer Institute (NCI)
EMD Serono
EMD Serono
Mayo Clinic
Mayo Clinic
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
ASLAN Pharmaceuticals
National Cancer Institute (NCI)
University of Pittsburgh
New Mexico Cancer Research Alliance
SWOG Cancer Research Network
University of Miami
Alliance for Clinical Trials in Oncology
SWOG Cancer Research Network
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Sanofi
Stanford University
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Washington University School of Medicine
National Cancer Institute (NCI)
National Cancer Institute (NCI)
INSYS Therapeutics Inc
Massachusetts General Hospital
M.D. Anderson Cancer Center